// App-Quantinova.ai

TPS3155 : Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting.

Researchers

Presenter

  • Razelle Kurzrock

Principal Investigators

  • Amy R. MacKenzie

  • Adham Adel Jurdi

  • Basem Goueli

  • Walter Bordogna

  • Magalie Hilton

  • Erika Ferreira

  • Venice Rosalie Archer

  • Bettyna Brivet-Jones

  • Johannes Noe

  • Abba Elizabeth Theogaraj

  • Lincoln Pasquina

  • Christine M. Lovly

Medical Centers

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Thomas Jefferson University, Philadelphia, PA

  • Austin Cancer Centers, Austin, TX

  • Great Lakes Cancer Center and University of Buffalo, Buffalo, NY

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Foundation Medicine, Inc., Boston, MA

  • Vanderbilt-Ingram Cancer Center, Vanderbilt University, School of Medicine, Nashville, TN

Locations

  • United States

  • Switzerland

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain cancer

  • Solid malignancies

  • Lung Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Alectinib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT02075840

  • NCT04644315

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved